{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T06:19:30Z","timestamp":1790662770851,"version":"4.1.0"},"reference-count":99,"publisher":"Elsevier BV","issue":"38","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,8,2]],"date-time":"2019-08-02T00:00:00Z","timestamp":1564704000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"GlaxoSmithKline Biologicals"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.vaccine.2019.07.098","type":"journal-article","created":{"date-parts":[[2019,8,13]],"date-time":"2019-08-13T08:13:19Z","timestamp":1565683999000},"page":"5670-5680","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":65,"title":["Adjuvant Systems for vaccines: 13\u202fyears of post-licensure experience in diverse populations have progressed the way adjuvanted vaccine safety is investigated and understood"],"prefix":"10.1016","volume":"37","author":[{"given":"B\u00e9atrice","family":"Laup\u00e8ze","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Herv\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberta","family":"Di Pasquale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda","family":"Tavares Da Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2019.07.098_b0005","doi-asserted-by":"crossref","first-page":"629","DOI":"10.2471\/BLT.16.178475","article-title":"Estimated economic impact of vaccinations in 73 low- and middle-income countries, 2001\u20132020","volume":"95","author":"Ozawa","year":"2017","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.vaccine.2019.07.098_b0010","doi-asserted-by":"crossref","unstructured":"GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2014; 385: p.117\u201371. 10.1016\/S0140-6736(14)61682-2.","DOI":"10.1016\/S0140-6736(14)61682-2"},{"key":"10.1016\/j.vaccine.2019.07.098_b0015","doi-asserted-by":"crossref","first-page":"320","DOI":"10.3390\/vaccines3020320","article-title":"Vaccine adjuvants: from 1920 to 2015 and Beyond","volume":"3","author":"Di Pasquale","year":"2015","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2019.07.098_b0020","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/nri2510","article-title":"Towards an understanding of the adjuvant action of aluminium","volume":"9","author":"Marrack","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.vaccine.2019.07.098_b0025","series-title":"Vaccine adjuvants. Understanding modern vaccines: perspectives in vaccinology","first-page":"89","author":"Garcon","year":"2011"},{"key":"10.1016\/j.vaccine.2019.07.098_b0030","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/21645515.2016.1225635","article-title":"From discovery to licensure, the Adjuvant System story","volume":"13","author":"Gar\u00e7on","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2019.07.098_b0035","doi-asserted-by":"crossref","first-page":"6186","DOI":"10.4049\/jimmunol.0901474","article-title":"AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity","volume":"183","author":"Didierlaurent","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2019.07.098_b0040","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.clim.2016.05.007","article-title":"Impact of adjuvants on CD4(+) T cell and B cell responses to a protein antigen vaccine: Results from a phase II, randomized, multicenter trial","volume":"169","author":"Leroux-Roels","year":"2016","journal-title":"Clin Immunol"},{"key":"10.1016\/j.vaccine.2019.07.098_b0045","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S1470-2045(11)70287-X","article-title":"Cross-protective efficacy of HPV-16\/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial","volume":"13","author":"Wheeler","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.vaccine.2019.07.098_b0050","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41541-018-0058-4","article-title":"Activation of the endoplasmic reticulum stress sensor IRE1alpha by the vaccine adjuvant AS03 contributes to its immunostimulatory properties","volume":"3","author":"Givord","year":"2018","journal-title":"npj Vaccines"},{"key":"10.1016\/j.vaccine.2019.07.098_b0055","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/j.vaccine.2011.01.011","article-title":"Adjuvant System AS03 containing \u03b1-tocopherol modulates innate immune response and leads to improved adaptive immunity","volume":"29","author":"Morel","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.07.098_b0060","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1586\/erv.11.192","article-title":"Development and evaluation of AS03, an Adjuvant System containing \u03b1-tocopherol and squalene in an oil-in-water emulsion","volume":"11","author":"Gar\u00e7on","year":"2012","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2019.07.098_b0065","doi-asserted-by":"crossref","first-page":"37229","DOI":"10.1038\/srep37229","article-title":"Investigating the effect of AS03 adjuvant on the plasma cell repertoire following pH1N1 influenza vaccination","volume":"6","author":"Galson","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2019.07.098_b0070","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1074\/jbc.M115.683011","article-title":"Identification of QS-21 as an Inflammasome-activating Molecular Component of Saponin Adjuvants","volume":"291","author":"Marty-Roix","year":"2016","journal-title":"J Biol Chem"},{"key":"10.1016\/j.vaccine.2019.07.098_b0075","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-017-0027-3","article-title":"Cellular and molecular synergy in AS01-adjuvanted vaccines results in an early IFN\u03b3 response promoting vaccine immunogenicity","volume":"2","author":"Coccia","year":"2017","journal-title":"npj Vaccines"},{"key":"10.1016\/j.vaccine.2019.07.098_b0080","doi-asserted-by":"crossref","first-page":"943","DOI":"10.3389\/fimmu.2017.00943","article-title":"Different adjuvants induce common innate pathways that are associated with enhanced adaptive responses against a model antigen in humans","volume":"8","author":"Burny","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2019.07.098_b0085","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1073\/pnas.1621489114","article-title":"Systems analysis of protective immune responses to RTS, S malaria vaccination in humans","volume":"114","author":"Kazmin","year":"2017","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2019.07.098_b0090","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1080\/14760584.2016.1213632","article-title":"Adjuvant system AS01: helping to overcome the challenges of modern vaccines","volume":"16","author":"Didierlaurent","year":"2017","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2019.07.098_b0095","doi-asserted-by":"crossref","first-page":"6672","DOI":"10.1016\/j.vaccine.2016.10.039","article-title":"Vaccine safety evaluation: Practical aspects in assessing benefits and risks","volume":"34","author":"Di Pasquale","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.07.098_b0100","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1080\/21645515.2015.1043501","article-title":"Safety assessment of adjuvanted vaccines: Methodological considerations","volume":"11","author":"Tavares Da Silva","year":"2015","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2019.07.098_b0105","series-title":"Immunopotentiators in Modern vaccines","first-page":"161","article-title":"Development and evaluation of AS04, a novel and improved adjuvant system containing MPL and aluminium salt","author":"Gar\u00e7on","year":"2006"},{"key":"10.1016\/j.vaccine.2019.07.098_b0110","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1517\/14712598.2011.573624","article-title":"Role of AS04 in human papillomavirus vaccine: mode of action and clinical profile","volume":"11","author":"Gar\u00e7on","year":"2011","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.vaccine.2019.07.098_b0115","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.c712","article-title":"Risk of miscarriage with bivalent vaccine against human papillomavirus (HPV) types 16 and 18: pooled analysis of two randomised controlled trials","volume":"340","author":"Wacholder","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2019.07.098_b0120","doi-asserted-by":"crossref","first-page":"5325","DOI":"10.1016\/j.vaccine.2017.08.042","article-title":"Results on exposure during pregnancy from a pregnancy registry for AS04-HPV-16\/18 vaccine","volume":"35","author":"Lopez-Fauqued","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.07.098_b0125","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1016\/j.vaccine.2013.01.042","article-title":"Optimal approaches to data collection and analysis of potential immune mediated disorders in clinical trials of new vaccines","volume":"31","author":"Tavares Da Silva","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.07.098_b0130","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.biologicals.2013.08.006","article-title":"Predictive markers of safety and immunogenicity of adjuvanted vaccines","volume":"41","author":"Mastelic","year":"2013","journal-title":"Biologicals"},{"key":"10.1016\/j.vaccine.2019.07.098_b0135","first-page":"5","article-title":"Evaluating potential immune-mediated adverse events following vaccination","volume":"3","author":"Farizo","year":"2015","journal-title":"VSQ"},{"key":"10.1016\/j.vaccine.2019.07.098_b0140","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/909406","article-title":"Application of \u201cSystems Vaccinology\u201d to Evaluate Inflammation and Reactogenicity of Adjuvanted Preventative Vaccines","volume":"2015","author":"Lewis","year":"2015","journal-title":"J Immunol Res"},{"key":"10.1016\/j.vaccine.2019.07.098_b0145","doi-asserted-by":"crossref","first-page":"4453","DOI":"10.1016\/j.vaccine.2011.04.046","article-title":"The safety evaluation of adjuvants during vaccine development: the AS04 experience","volume":"29","author":"Gar\u00e7on","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.07.098_b0150","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1517\/14712598.8.2.235","article-title":"Safety and immunogenicity of a new hepatitis B vaccine for the protection of patients with renal insufficiency including pre-haemodialysis and haemodialysis patients","volume":"8","author":"Beran","year":"2008","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.vaccine.2019.07.098_b0155","doi-asserted-by":"crossref","first-page":"6884","DOI":"10.1016\/j.vaccine.2015.07.024","article-title":"Risk of spontaneous abortion and other pregnancy outcomes in 15\u201325 year old women exposed to human papillomavirus-16\/18 AS04-adjuvanted vaccine in the United Kingdom","volume":"33","author":"Baril","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.07.098_b0160","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1080\/21645515.2016.1199308","article-title":"Risk of new onset autoimmune disease in 9- to 25-year-old women exposed to human papillomavirus-16\/18 AS04-adjuvanted vaccine in the United Kingdom","volume":"12","author":"Willame","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2019.07.098_b0165","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1002\/pds.3593","article-title":"Post-licensure safety surveillance for human papillomavirus-16\/18-AS04-adjuvanted vaccine: more than 4 years of experience","volume":"23","author":"Angelo","year":"2014","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.vaccine.2019.07.098_b0170","doi-asserted-by":"crossref","first-page":"6630","DOI":"10.1016\/j.vaccine.2008.09.049","article-title":"Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines","volume":"26","author":"Verstraeten","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.07.098_b0175","unstructured":"GSK Clinical Trials Rgister. Study ID 205639. https:\/\/www.gsk-clinicalstudyregister.com\/study\/205639?search=study&search_terms=205639#csr [Accessed 04 June 2018]."},{"key":"10.1016\/j.vaccine.2019.07.098_b0180","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1038\/bjc.2014.479","article-title":"Reduction of low- and high-grade cervical abnormalities associated with high uptake of the HPV bivalent vaccine in Scotland","volume":"111","author":"Pollock","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.vaccine.2019.07.098_b0185","unstructured":"Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 March 2018. Available from https:\/\/www.ema.europa.eu\/documents\/minutes\/minutes-chmp-meeting-19-22-march-2018_en.pdf [Accessed 11 October 2018]."},{"key":"10.1016\/j.vaccine.2019.07.098_b0190","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.ebiom.2015.07.003","article-title":"Investigating reports of complex regional pain syndrome: an analysis of HPV-16\/18-adjuvanted vaccine post-licensure data","volume":"2","author":"Huygen","year":"2015","journal-title":"EBioMedicine"},{"key":"10.1016\/j.vaccine.2019.07.098_b0195","unstructured":"European Medicines Agency. Human medicines. Human papillomavirus vaccines. HPV vaccines: EMA confirms evidence does not support that they cause CRPS or POTS. Available from http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/referrals\/Human_papillomavirus_vaccines\/human_referral_prac_000053.jsp&mid=WC0b01ac05805c516f. [Accessed 13 June 2018]."},{"key":"10.1016\/j.vaccine.2019.07.098_b0200","unstructured":"Global Advisory Committee on Vaccine Safety, 30 November - 1 December 2016. Wkly Epidemiol Rec 2017; 92: p. 13\u201320."},{"key":"10.1016\/j.vaccine.2019.07.098_b0205","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.ijgo.2013.09.009","article-title":"International Federation of Gynecology and Obstetrics. Safety of HPV vaccination: a FIGO statement","volume":"123","author":"Denny","year":"2013","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.vaccine.2019.07.098_b0210","unstructured":"National Centre for Immunisation Research & Surveillance. NCIRS Position Statement on HPV Vaccination. Last updated April 2016. Available from http:\/\/www.ncirs.edu.au\/consumer-resources\/ncirs-position-statement-on-hpv-vaccination\/ [Accessed 26 April 2018]."},{"key":"10.1016\/j.vaccine.2019.07.098_b0215","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1093\/cid\/ciw796","article-title":"Japanese Media and the HPV Vaccine Saga","volume":"64","author":"Larson","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2019.07.098_b0220","unstructured":"World Health Organisation. WHO activities in avian influenza and pandemic influenza preparedness. January-December 2006. Available from http:\/\/www.who.int\/influenza\/resources\/documents\/WHO_CDS_EPR_GIP_2006_6.pdf. [Accessed 15 June 2018]."},{"key":"10.1016\/j.vaccine.2019.07.098_b0225","unstructured":"European Medicines Agency. Adjupanrix (previously Pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) GlaxoSmithKline Biologicals). Available at http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/001206\/human_med_001214.jsp&mid=WC0b01ac058001d124. [Accesssed 06 June 2018]."},{"key":"10.1016\/j.vaccine.2019.07.098_b0230","unstructured":"US Food and Drug Administration. Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted. Available from https:\/\/www.fda.gov\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/ucm376289.htm. [Accessed 06 June 2018]."},{"key":"10.1016\/j.vaccine.2019.07.098_b0235","unstructured":"European Medicines Agency. Pandemic influenza A(H1N1)v vaccines authorised via the core dossier procedure. Explanatory note on scientific considera tions regarding the licensing of pandemic A(H1N1)v vaccines. London, 24 September 2009. EMEA\/608259\/2009rev. Available from http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Medicine_QA\/2009\/11\/WC500007567.pdf. [Accessed 15 June 2018]."},{"key":"10.1016\/j.vaccine.2019.07.098_b0240","unstructured":"European Medicines Agency. CHMP Recommendations for the Pharmacovigilance Plan as part of the Risk Management Plan to be submitted with the Marketing Authorisation Application for a Pandemic Influenza Vaccine. Revision 1.1. EMEA\/359381\/2009. Available from www.ema.europa.eu\/docs\/en_GB\/document_library\/Report\/2010\/01\/WC500051739.pdf. [Acccessed 15 June 2018]."},{"issue":"23","key":"10.1016\/j.vaccine.2019.07.098_b0245","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1016\/j.vaccine.2019.04.048","article-title":"Safety of AS03-adjuvanted influenza vaccines: A review of the evidence","volume":"37","author":"Cohet","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.07.098_b0250","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-009264","article-title":"Effect of the adjuvanted (AS03) A\/H1N1 2009 pandemic influenza vaccine on the risk of rejection in solid organ transplant recipients in England: a self-controlled case series","volume":"6","author":"Cohet","year":"2016","journal-title":"BMJ Open"},{"key":"10.1016\/j.vaccine.2019.07.098_b0255","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1186\/2047-783X-16-7-289","article-title":"Acceptance and tolerability of an adjuvanted nH1N1 vaccine in HIV-infected patients in the Cologne-Bonn cohort","volume":"16","author":"Steffens","year":"2011","journal-title":"Eur J Med Res"},{"key":"10.1016\/j.vaccine.2019.07.098_b0260","doi-asserted-by":"crossref","first-page":"6358","DOI":"10.1016\/j.vaccine.2011.04.114","article-title":"Pregnancy and safety outcomes in women vaccinated with an AS03-adjuvanted split virion H1N1 (2009) pandemic influenza vaccine during pregnancy: a prospective cohort study","volume":"29","author":"Tavares","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.07.098_b0265","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1093\/infdis\/jiq014","article-title":"Age-specific effectiveness of an oil-in-water adjuvanted pandemic (H1N1) 2009 vaccine against confirmed infection in high risk groups in England","volume":"203","author":"Andrews","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2019.07.098_b0270","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/ejh.12094","article-title":"Adjuvanted influenza a (H1N1) 2009 vaccine in patients with hematological diseases: good safety and immunogenicity even in chemotherapy-treated patients","volume":"90","author":"Cherif","year":"2013","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.vaccine.2019.07.098_b0275","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.3389\/fimmu.2017.01760","article-title":"AS03- and MF59-adjuvanted influenza vaccines in children","volume":"8","author":"Wilkins","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2019.07.098_b0280","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.vaccine.2015.12.024","article-title":"A systematic review and meta-analysis on the safety of newly adjuvanted vaccines among children","volume":"34","author":"Stassijns","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.07.098_b0285","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1093\/infdis\/jis487","article-title":"University of Nottingham Influenza and the ImmunoCompromised Study Group, Nguyen-Van-Tam JS. Influenza vaccination for immunocompromised patients: systematic review and meta-analysis by etiology","volume":"206","author":"Beck","year":"2012","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2019.07.098_b0290","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/oxfordjournals.aje.a112795","article-title":"Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976\u20131977","volume":"110","author":"Schonberger","year":"1979","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2019.07.098_b0295","doi-asserted-by":"crossref","first-page":"7123","DOI":"10.1016\/j.vaccine.2012.09.032","article-title":"Autoimmune disorders after immunisation with Influenza A\/H1N1 vaccines with and without adjuvant: EudraVigilance data and literature review","volume":"30","author":"Isai","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.07.098_b0300","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0082222","article-title":"Guillain-Barr\u00e9 syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccines: a multinational self-controlled case series in Europe","volume":"9","author":"Romio","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2019.07.098_b0305","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1016\/j.vaccine.2013.06.032","article-title":"International collaboration to assess the risk of Guillain Barr\u00e9 Syndrome following Influenza A (H1N1) 2009 monovalent vaccines","volume":"31","author":"Dodd","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.07.098_b0310","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1001\/jama.2012.7342","article-title":"Risk of Guillain-Barr\u00e9 syndrome following H1N1 influenza vaccination in Quebec","volume":"308","author":"De Wals","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2019.07.098_b0315","first-page":"1","article-title":"Pandemrix\u2122 and narcolepsy: A critical appraisal of the observational studies","volume":"12","author":"Verstraeten","year":"2015","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2019.07.098_b0320","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.smrv.2017.06.006","article-title":"Incidence of narcolepsy after H1N1 influenza and vaccinations: Systematic review and meta-analysis","volume":"38","author":"Sarkanen","year":"2018","journal-title":"Sleep Med Rev"},{"key":"10.1016\/j.vaccine.2019.07.098_b0325","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0108489","article-title":"Risk of narcolepsy associated with inactivated adjuvanted (AS03) A\/H1N1 (2009) pandemic influenza vaccine in Quebec","volume":"9","author":"Montplaisir","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2019.07.098_b0330","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1080\/21645515.2016.1168954","article-title":"Evaluation of potential immunogenicity differences between Pandemrix and Arepanrix","volume":"12","author":"Canelle","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2019.07.098_b0335","doi-asserted-by":"crossref","first-page":"6202","DOI":"10.1016\/j.vaccine.2018.08.008","article-title":"Narcolepsy and adjuvanted pandemic influenza A (H1N1) 2009 vaccines - Multi-country assessment","volume":"36","author":"Weibel","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.07.098_b0340","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1002\/ana.22587","article-title":"Narcolepsy onset is seasonal and increased following the 2009 H1N1 pandemic in China","volume":"70","author":"Han","year":"2011","journal-title":"Ann Neurol"},{"key":"10.1016\/j.vaccine.2019.07.098_b0345","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/ana.23799","article-title":"Decreased incidence of childhood narcolepsy 2 years after the 2009 H1N1 winter flu pandemic","volume":"73","author":"Han","year":"2013","journal-title":"Ann Neurol"},{"key":"10.1016\/j.vaccine.2019.07.098_b0350","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.5665\/sleep.5060","article-title":"Incidence of Narcolepsy in Germany","volume":"38","author":"Oberle","year":"2015","journal-title":"Sleep"},{"key":"10.1016\/j.vaccine.2019.07.098_b0355","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1003880","article-title":"Genome wide analysis of narcolepsy in China implicates novel immune loci and reveals changes in association prior to versus after the 2009 H1N1 influenza pandemic","volume":"9","author":"Han","year":"2013","journal-title":"PLoS Genet"},{"key":"10.1016\/j.vaccine.2019.07.098_b0360","unstructured":"European Medicines Agency. Committee for Medicinal Products for Human Use. Assessment report. Pandemrix. 28 April 2016. EMA\/CHMP\/566359\/2015."},{"key":"10.1016\/j.vaccine.2019.07.098_b0365","doi-asserted-by":"crossref","first-page":"E12323","DOI":"10.1073\/pnas.1818150116","article-title":"Autoimmunity to hypocretin and molecular mimicry to flu in type 1 narcolepsy","volume":"115","author":"Luo","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2019.07.098_b0370","unstructured":"European Medicines Agency, Pandemrix. EPAR summary for the public. EMA\/388182\/2016. EMEA\/H\/C\/000832. Available from http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Summary_for_the_public\/human\/000832\/WC500038122.pdf. [Accessed 11 June 2018]."},{"key":"10.1016\/j.vaccine.2019.07.098_b0375","doi-asserted-by":"crossref","unstructured":"RTS,S Clinical Trials Partnership. Efficacy and safety of RTS,S\/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet 2015; 386: p. 31\u201345. doi: 10.1016\/S0140-6736(15)60721-8.","DOI":"10.1016\/S0140-6736(15)60721-8"},{"key":"10.1016\/j.vaccine.2019.07.098_b0380","unstructured":"European Medicines Agency. Mosquirix H-W-2300. Product information. Available from http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/document_listing\/document_listing_000395.jsp&mid= [Accesseed 13 June 2018]."},{"key":"10.1016\/j.vaccine.2019.07.098_b0385","doi-asserted-by":"crossref","unstructured":"RTS,S Clinical Trials Partnership. A phase 3 trial of RTS,S\/AS01 malaria vaccine in African infants. N Eng J Med 2012; 367: p. 2284\u201395. doi: 10.1056\/NEJMoa1208394","DOI":"10.1056\/NEJMoa1208394"},{"key":"10.1016\/j.vaccine.2019.07.098_b0390","doi-asserted-by":"crossref","unstructured":"RTS SCTP, Agnandji ST, Lell B, Soulanoudjingar SS, Fernandes JF, Abossolo BP, et al. First results of phase 3 trial of RTS,S\/AS01 malaria vaccine in African children. N Engl J Med 2011; 365: p. 1863\u201375. doi: 10.1056\/NEJMoa1102287","DOI":"10.1056\/NEJMoa1102287"},{"key":"10.1016\/j.vaccine.2019.07.098_b0395","doi-asserted-by":"crossref","unstructured":"RTS,S Clinical Trials Partnership. Efficacy and safety of the RTS,S\/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites. PLoS Med 2014; 11: e1001685. doi: 10.1371\/journal.pmed.1001685.","DOI":"10.1371\/journal.pmed.1001685"},{"key":"10.1016\/j.vaccine.2019.07.098_b0400","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1016\/S0140-6736(15)00693-5","article-title":"RTS, S\/AS01 malaria vaccine and child mortality","volume":"386","author":"Aaby","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2019.07.098_b0405","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1016\/S0140-6736(15)00694-7","article-title":"RTS, S\/AS01 malaria vaccine and child mortality","volume":"386","author":"Muller","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2019.07.098_b0410","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.vaccine.2016.12.067","article-title":"Could the RTS, S\/AS01 meningitis safety signal really be a protective effect of rabies vaccine?","volume":"35","author":"Gessner","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.07.098_b0415","doi-asserted-by":"crossref","first-page":"e00514","DOI":"10.1128\/mBio.00514-16","article-title":"RTS, S Malaria Vaccine and Increased Mortality in Girls","volume":"7","author":"Klein","year":"2016","journal-title":"MBio"},{"key":"10.1016\/j.vaccine.2019.07.098_b0420","unstructured":"GSK Clinical Trials Registry. Study No.: 110021 (MALARIA-055 PRI). Available from https:\/\/www.gsk-clinicalstudyregister.com\/files2\/9a7b7726-34e2-418d-bea6-c3fb071fd51c Accessed 12 June 2018."},{"key":"10.1016\/j.vaccine.2019.07.098_b0425","first-page":"1","article-title":"Safety profile of the RTS, S\/AS01 malaria vaccine in infants and children: additional data from a phase III randomized controlled trial in sub-Saharan Africa","author":"Guerra Mendoza","year":"2019","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2019.07.098_b0430","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","article-title":"Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults","volume":"372","author":"Lal","year":"2015","journal-title":"N Eng J Med"},{"key":"10.1016\/j.vaccine.2019.07.098_b0435","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","article-title":"Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older","volume":"375","author":"Cunningham","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2019.07.098_b0440","doi-asserted-by":"crossref","unstructured":"McElhaney JE, Lal H, Cunningham A, Levin MJ, Chlibek R, Diez-Domingo J. Efficacy, Immunogenicity and Safety of an Investigational Subunit Adjuvanted Herpes Zoster Vaccine in Adults Aged 60 Years and Older: Results from the ZOE-50 and ZOE-70 Efficacy Studies. IDWeek, New Orleans, USA, 26\u201330 October 2016.","DOI":"10.1093\/ofid\/ofw194.40"},{"key":"10.1016\/j.vaccine.2019.07.098_b0445","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1086\/600120","article-title":"Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS, S\/AS01B and RTS, S\/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection","volume":"200","author":"Kester","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2019.07.098_b0450","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.4049\/jimmunol.1400948","article-title":"Enhancement of Adaptive Immunity by the Human Vaccine Adjuvant AS01 Depends on Activated Dendritic Cells","volume":"193","author":"Didierlaurent","year":"2014","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2019.07.098_b0455","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1080\/14760584.2018.1495565","article-title":"Development of a recombinant adjuvanted herpes zoster subunit vaccine and its implications for shingles prevention","volume":"17","author":"Lecrenier","year":"2018","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2019.07.098_b0460","unstructured":"de la Serna J, Campora L, Chandrasekar P, El Idrissi M, Gaidano G, L\u00f3pez Fauqued M, et al. Efficacy and Safety of an Adjuvanted Herpes Zoster Subunit Vaccine in Autologous Hematopoietic Stem Cell Transplant Recipients 18 Years of Age or Older: First Results of the Phase 3 Randomized, Placebo-Controlled ZOE-HSCT Clinical Trial. LBA2. BMT Tandem meetings. Salt lake City, Utah. Feb 21-25, 2018. Available at https:\/\/bmt.confex.com\/tandem\/2018\/meetingapp.cgi\/Paper\/11724. Accessed 12 April 2018"},{"key":"10.1016\/j.vaccine.2019.07.098_b0465","unstructured":"Sullivan K, Abhyankar S, Campora L, Cellini C, Chandrasekar P, Serna Jdl, et al. Immunogenicity and safety of an adjuvanted herpes zoster subunit vaccine in adult autologous hematopoietic stem cell transplant recipients: phase 3, randomized, placebo-controlled, ZOE-HSCT clinical trial. Abstractr OS9-2. 44th Annual meeting of the European Society for Blood and Marrow Transplantation; March 18-21, 2018; Lisbon, Portugal."},{"key":"10.1016\/j.vaccine.2019.07.098_b0470","unstructured":"Malaria vaccine: WHO position paper-January 2016. Wkly Epidemiol Rec 2016; 91: p. 33\u201351."},{"key":"10.1016\/j.vaccine.2019.07.098_b0475","unstructured":"Baril L, Pircon JY, Bozonnat M-C, Haine V, Usuf E, Garric E, et al. Designing epidemiological studies for the post approval plan of the RTS,S\/AS01 malaria vaccine in sub-Saharan African countries. [abstract] Malaria Vaccines for the World, 2-4 May 2016, Leiden, The Netherlands."},{"key":"10.1016\/j.vaccine.2019.07.098_b0480","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1016\/j.vaccine.2017.04.058","article-title":"Challenges in conducting post-authorisation safety studies (PASS): A vaccine manufacturer's view","volume":"35","author":"Cohet","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.07.098_b0485","unstructured":"Burny W, Callegaro A, Fissette L, Herve C, Van den Bergh R, Esen M, et al. Associations between reactogenicity symptoms and parameters of the early immune response to adjuvanted vaccines in humans [abstract]. Keystone Sympsia, Seattle, US. October 8-13, 2014."},{"key":"10.1016\/j.vaccine.2019.07.098_b0490","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2018.05.001","article-title":"Correlates of adjuvanticity: A review on adjuvants in licensed vaccines","author":"Del Giudice","year":"2018","journal-title":"Semin Immunol"},{"key":"10.1016\/j.vaccine.2019.07.098_b0495","article-title":"Prevalence of cervical disease at age 20 after immunisation with bivalent HPV vaccine at age 12\u201313 in Scotland: retrospective population study","volume":"365","author":"Palmer","year":"2019","journal-title":"BMJ"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19310199?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19310199?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:34:46Z","timestamp":1759401286000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X19310199"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":99,"journal-issue":{"issue":"38","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S0264410X19310199"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.07.098","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adjuvant Systems for vaccines: 13\u202fyears of post-licensure experience in diverse populations have progressed the way adjuvanted vaccine safety is investigated and understood","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.07.098","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 GlaxoSmithKline Biologicals S.A. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}